MARC Record from marc_columbia

LEADER: 03384cam a22004213i 4500
001 12353194
005 20170221151926.0
008 160804s2016 dcua b 000 0 eng d
019 $a956688029
020 $a030944232X$q(paperback)
020 $a9780309442329$q(paperback)
035 $a(OCoLC)ocn955020058
035 $a(OCoLC)955020058$z(OCoLC)956688029
035 $a(NNC)12353194
040 $aYDXCP$beng$erda$cYDXCP$dBTCTA$dOCLCQ$dSOI$dOCLCO$dYDX$dOCLCO$dOCLCA
090 $aRC271.I45$bB35 2016
100 1 $aBalogh, Erin,$erapporteur.
245 10 $aPolicy issues in the clinical development and use of immunotherapy for cancer treatment :$bproceedings of a workshop / Erin Balogh, Kimberly Maxfield, Margie Patlak, and Sharyl J. Nass, rapporteurs ; National Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division ; the National Academies of Sciences, Engineering, Medicine.
264 1 $aWashington, DC :$bNational Academies Press,$c[2016]
300 $axxi, 112 pages :$billustrations (some color) ;$c23 cm
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
338 $avolume$bnc$2rdacarrier
520 $a"Immunotherapy is a form of cancer therapy that harnesses the body immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, it is hoped that continued immunotherapy research and development will produce better cancer treatments that improve patient outcomes. With this promise, however, there is also recognition that the clinical and biological landscape for immunotherapies is novel and not yet well understood. For example, adverse events with immunotherapy treatment are quite different from those experienced with other types of cancer therapy. Similarly, immunotherapy dosing, therapeutic responses, and response time lines are also markedly different from other cancer therapies. To examine these challenges and explore strategies to overcome them, the National Academies of Sciences, Engineering, and Medicine held a workshop in February and March of 2016. This report summarizes the presentations and discussions from the workshop"--Publisher's description.
504 $aIncludes bibliographical references (pages 94-102).
505 0 $aBiology of the immune response to tumors -- Cancer immunotherapies -- Drug development challenges for immunotherapies -- Collaboration and information exchange -- Clinical implementation -- Value of immunotherapy.
650 0 $aCancer$xImmunotherapy$vCongresses.
650 12 $aNeoplasms$ximmunology.
650 12 $aNeoplasms$xtherapy.
650 22 $aImmunotherapy.
650 22 $aImmunotherapy$xadverse effects.
650 2 $aCongresses as Topic.
700 1 $aMaxfield, Kimberly,$erapporteur.
700 1 $aPatlak, Margie,$erapporteur.
700 1 $aNass, Sharyl J.,$erapporteur.
710 2 $aNational Cancer Policy Forum (U.S.),$esponsoring body.
711 2 $aPolicy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment (Workshop)$d(2016 :$cWashington, D.C.),$jauthor.
852 00 $boff,sci$hRC271.I45$iB35 2016g